Abstract P1-01-10: Positron emission mammography in assessment of the clinicopathological characteristics of breast cancers

Abstract

Abstract Background: Breast cancer is the most prevalent malignant neoplasm in women. Early detection and personalized treatment are very important to decrease mortality. Positron emission mammography(PEM) is a newly developed breast imaging technology using the positron emission tomography(PET) radiopharmaceutical 18F-fluoro-deoxy-D-glucose(18FDG). We investigated the correlation between PEM and known prognostic markers, including estrogen receptor(ER), progesterone receptor(PR), human epidermal growth factor receptor(HER2) status, tumor histology, nuclear grade, and the number of Ki-67-positive tumor cells/10 HPF(Ki-67 index). Methods: Fifty-eight patients were included in this study. PEM imaging was performed on a commercially available PEM unit. Maximum PEM uptake value(PUVmax) and lesion-to-background(LTB) ratio were determined. All resected specimens were evaluated by our institution’s pathology department. PUVmax and LTB ratios were compared with ER and PR status, tumor histology, and nuclear grades. The correlation coefficients between maximum PEM uptake value or LTB and the Ki-67 index were calculated. Results: PUVmax values were significantly different between ductal carcinoma in situ and invasive ductal carcinoma(P = 0.033). PUVmax and LTB showed significant differences between nuclear grade 1 and nuclear grade 3(PUVmax: P = 0.027, LTB: 0.0043). PUVmax, LTB, and Ki-67 index correlated significantly; PUVmax and Ki-67 index: correlation coefficient = 0.558, P = 0.000125; LTB and Ki-67 index: correlation coefficient = 0.572, P = 0.000075. Conclusions: PUVmax and LTB showed remarkable correlation with nuclear grades and the Ki-67 index, suggesting PEM’s utility in assessing the clinicopathological characteristics of breast cancer. Citation Format: Jun Ito, Toshihiko Sato. Positron emission mammography in assessment of the clinicopathological characteristics of breast cancers [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P1-01-10.